Ocelot Bio

ocelotbio.com

Ocelot Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with end-stage liver disease (ESLD). Their lead candidate, OCE-205, is a therapeutic peptide targeting portal hypertension complications such as hepatorenal syndrome and ascites. With a focus on improving patient outcomes, Ocelot Bio is in Phase 2 clinical development for HRS-AKI and has received FDA Orphan Drug Designation for OCE-205. The company aims to transform treatment options for ESLD patients, enhancing survival rates and facilitating access to liver transplantation.